BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Queensland Health
Argus Health
Express Scripts
Julphar
AstraZeneca
Fuji
QuintilesIMS
Chinese Patent Office

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,808,737

« Back to Dashboard

Which drugs does patent 8,808,737 protect, and when does it expire?

Patent 8,808,737 protects OPANA ER and is included in one NDA.
Summary for Patent: 8,808,737
Title:Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
Inventor(s): Ahdieh; Harry (Lincoln University, PA)
Assignee: Endo Pharmaceuticals Inc. (Malvern, PA)
Application Number:12/716,973
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,808,737

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-004 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-005 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-006 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-007 Dec 9, 2011 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,808,737

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,789,103 Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
US Department of Justice
Boehringer Ingelheim
Julphar
Accenture
Cantor Fitzgerald
Healthtrust
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot